Advertisement

Topics

Tocilizumab shows positive results for giant cell arteritis in phase 3 trial

16:08 EDT 27 Jul 2017 | Healio

In a phase 3 trial, tocilizumab showed positive phase 3 trial results for patients with giant cell arteritis.“The publication of these phase 3 results in The New England Journal of Medicine validates the significance of our considerable basic and clinical autoimmune disease research in medical practice,” Sandra Horning, MD, chief medical officer and head of Global Product Development, said in a press release from Genentech. “The data from the GiACTA supported the FDA approval of the first new treatment option for patients with [giant cell arteritis] GCA in more than 50 years, and we are committed to continuing to explore new treatment options for autoimmune diseases with significant unmet medical need.”

Original Article: Tocilizumab shows positive results for giant cell arteritis in phase 3 trial

NEXT ARTICLE

More From BioPortfolio on "Tocilizumab shows positive results for giant cell arteritis in phase 3 trial"

Quick Search
Advertisement
 

Relevant Topics

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...